Article

NIH blocks effort for generic latanoprost

Washington, DC-Pfizer Ophthalmic's patented formulation of latanoprost (Xalatan) is safe from competition for now, after the National Institutes of Health (NIH) has refused to step in and license generic versions.

Washington, DC-Pfizer Ophthalmic's patented formulation of latanoprost (Xalatan) is safe from competition for now, after the National Institutes of Health (NIH) has refused to step in and license generic versions.

A nonprofit company formed by consumer advocates had asked the government to allow it to produce cheaper, generic versions of latanoprost before Pfizer Ophthalmic's patent expires July 28, 2006. The company, Essential Inventions, alleged that Pfizer Ophthalmics priced the drug above the market and failed to make the drug, which was developed in part with federal grants, available "on reasonable terms."

According to the company's interpretation of the 1980 Bayh-Dole Act, that would allow the NIH to "march in" and grant licenses to competitors.

"Pfizer [Ophthalmics] has met the standard for achieving practical application of the applicable patents by its manufacture, practice, and operation of latanoprost and the drug's availability and use by the public," the NIH said. "Because the market dynamics for all products developed pursuant to licensing rights under the Bayh-Dole Act could be altered if prices on such products were directed in any way by the NIH, the NIH believes that the extraordinary remedy of march-in is not an appropriate means of controlling prices."

Instead, the agency said, the issue of whether drugs should be sold for the same price in the United States as they are in Canada and Europe is for Congress to decide.

Pfizer Ophthalmics spokesman Daniel Watts said he was unaware of any previous efforts against the company to engineer this kind of "march in."

"It was an appropriate decision," Watts said.

Essential Inventions general counsel Robert Weissman, who was not immediately available for comment, said in a statement that the company would appeal the decision to the secretary for Health and Human Services. He said the NIH misinterprets the statutory language and benefits "big pharma."

"It mistakenly asserts that a licensee need only put a product on the market, at any price," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.